Saturday 17 October 2026
Export CARM’s income statement to Excel — free account
Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023. In the quarter to September 2025, revenue grew 392.0%, EPS grew 445.2% and free cash flow grew 114.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.02
−100.00%
Follow CARM
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | 3 | 4 |
+8 more TTM periods Free account |
| (134.11%) | 216.35% | 394.03% | 8,783.88% | ||
| 33.09% | (153.46%) | (113.13%) | (100.78%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(853.72%) | 1,060.73% | (1,447.53%) | (497.55%) | |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.52) | (0.88) | (1.13) | (1.45) | |
Free Cash Flow |
(21.73) | (36.66) | (47.14) | (60.04) | |
Capital Expenditures |
0.69 | 0.69 | 0.42 | (0.12) | |
| Other line items | |||||
Cash ROIC |
(1,137.59%) | 83.30% | 162.99% | 601.60% | |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
48.83% | 0.00% | 257.30% | 303.96% | |
Selling, General and Administrative Expense of Revenue |
25.76% | 0.00% | 103.19% | 112.76% | |
Share Based Compensation of Revenue |
3.95% | 0.00% | 15.53% | 18.59% | |
Operating CF/Net income |
(2.79) | 0.76 | 0.94 | 0.99 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.76 | |
Capex/Depreciation |
0.52 | 0.33 | 0.18 | (0.04) | |
Revenue per Share |
1.34 | 0.00 | 0.48 | 0.47 | |
Operating CF per Share |
(0.54) | (0.89) | (1.14) | (1.45) | |
Capex per Share |
0.02 | 0.02 | 0.01 | 0.00 | |
Capex to Sales |
(0.01) | 0.00 | (0.02) | 0.01 |
Columns are period end dates